Erschienen in:
01.10.2005 | Editorial
Efficacy of micafungin for the treatment of candidemia
verfasst von:
D. Andes, N. Safdar
Erschienen in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Ausgabe 10/2005
Einloggen, um Zugang zu erhalten
Excerpt
Candida species are responsible for up to 15% of nosocomial infections worldwide and are the fourth leading cause of nosocomial bloodstream infection in the USA [
1,
2]. Despite an expanding antifungal armamentarium, morbidity and mortality rates of candidemia remain high [
2,
3]. Current antifungal treatment options include drugs from the polyene, triazole, and now echinocandin classes [
4]. The addition of the echinocandins to this group of compounds has provided a safe, potent, and broad-spectrum treatment option for invasive
Candida infections [
5‐
7]. …